Cardiac CIP protein regulates dystrophic cardiomyopathy
Xin He,Jianming Liu,Fei Gu,Jinghai Chen,Yao Wei Lu,Jian Ding,Haipeng Guo,Mao Nie,Masaharu Kataoka,Zhiqiang Lin,Xiaoyun Hu,Huaqun Chen,Xinxue Liao,Yugang Dong,Wang Min,Zhong-Liang Deng,William T Pu,Zhan-Peng Huang,Da-Zhi Wang,William T. Pu
DOI: https://doi.org/10.1016/j.ymthe.2021.08.022
IF: 12.91
2022-02-01
Molecular Therapy
Abstract:Heart failure is a leading cause of fatality in Duchenne muscular dystrophy (DMD) patients. Previously, we discovered that cardiac and skeletal-muscle-enriched CIP proteins play important roles in cardiac function. Here, we report that CIP, a striated muscle-specific protein, participates in the regulation of dystrophic cardiomyopathy. Using a mouse model of human DMD, we found that deletion of CIP leads to dilated cardiomyopathy and heart failure in young, non-syndromic mdx mice. Conversely, transgenic overexpression of CIP reduces pathological dystrophic cardiomyopathy in old, syndromic mdx mice. Genome-wide transcriptome analyses reveal that molecular pathways involving fibrogenesis and oxidative stress are affected in CIP-mediated dystrophic cardiomyopathy. Mechanistically, we found that CIP interacts with dystrophin and calcineurin (CnA) to suppress the CnA-Nuclear Factor of Activated T cells (NFAT) pathway, which results in decreased expression of Nox4, a key component of the oxidative stress pathway. Overexpression of Nox4 accelerates the development of dystrophic cardiomyopathy in mdx mice. Our study indicates CIP is a modifier of dystrophic cardiomyopathy and a potential therapeutic target for this devastating disease.
genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology